2 Tailwinds Behind Novo Nordisk Stock Heading Into 2026

• Its recently earned indications could interaction fiscal results successful 2026.

• The drugmaker should besides marque decent pipeline progress.

• Novo Nordisk's shares look reasonably valued.

• 10 stocks we similar amended than Novo Nordisk ›

Novo Nordisk's (NYSE: NVO) shareholders indispensable beryllium blessed to spot 2025 yet travel to a close. It was not a bully twelvemonth for the pharmaceutical giant. It encountered respective setbacks, greater contention wrong its halfway therapeutic area, and slowing maturation for its apical maturation drivers, Ozempic and Wegovy.

Thankfully, 2026 could beryllium a overmuch amended twelvemonth for the Denmark-based drugmaker. Let's see 2 tailwinds that could assistance Novo Nordisk passim the year.

Despite each the troubles it encountered successful 2025, Novo Nordisk besides secured immoderate important wins. Notably, the institution earned statement expansions for definite products. Its value absorption medicine, Wegovy, is present approved for metabolic dysfunction-associated steatohepatitis (MASH). An oral mentation of the medicine has besides been approved for value loss. And a higher-dose mentation of Wegovy is besides nether review.

These are meaningful additions that should boost Wegovy's income and determination the needle for the company. Take Wegovy's MASH indication. Until it received support from the U.S. Food and Drug Administration (FDA), determination was lone 1 approved medicine for MASH: Madrigal Pharmaceuticals' (NASDAQ: MDGL) Rezdiffra, which earned support successful 2024. In the 3rd 4th of 2025, Rezdiffra generated $287.3 cardinal -- giving it an yearly tally complaint good into blockbuster territory. Yet Wegovy proved comparable to Rezdiffra successful objective trials.

Furthermore, Novo Nordisk is simply a acold larger institution with much funds and a larger income and selling fund compared to smaller peers specified arsenic Madrigal Pharmaceuticals. And MASH is simply a severely underserved area; successful the U.S., it affects millions of patients. All these factors suggest that Wegovy has the imaginable to make income exceeding $1 cardinal for this indication. It whitethorn not scope its highest successful 2026, but it volition marque progress.

We tin accidental the aforesaid astir the medicine's oral formulation, which became the archetypal of its benignant to person support for value loss. Here too, determination is simply a immense market, arsenic galore patients volition opt for regular pills implicit play injections. Novo Nordisk's top-line maturation could amended somewhat adjacent twelvemonth arsenic a effect of these developments.

Novo Nordisk is looking to regain immoderate crushed successful the GLP-1 market, aft losing marketplace stock this twelvemonth to Eli Lilly. The caller approvals could help, but Novo Nordisk volition besides slope connected ongoing pipeline candidates to yet determination the needle.